Massive dilutive event relative to market cap. Monitor for stockholder approval of Series A-1 warrants and potential further dilution. The company's cash runway may be extended but at extreme cost to existing shareholders. Expect continued downward pressure on the stock.
Price Chart
Executive Summary
Arcadia Biosciences closed a private placement raising approximately $4 million in gross proceeds through the sale of common stock and preferred investment options. The dilutive offering, priced at $1.03 per share, adds significant share overhang with warrants exercisable at $0.91, and proceeds are earmarked for working capital. Given the company's $2M market cap, this offering represents massive dilution and underscores ongoing capital needs.
Key Financial Metrics
Key Facts
- Closed private placement of 3,883,496 shares of common stock (or pre-funded warrants) at $1.03 per share.
- Also issued Series A-1 and A-2 preferred investment options, each to purchase up to 3,883,496 shares at $0.91 per share.
- Aggregate gross proceeds of approximately $4 million.
- Net proceeds to be used for working capital and general corporate purposes.
- H.C. Wainwright & Co. acted as exclusive placement agent.
- Company's market cap is approximately $2 million, making the offering size roughly 200% of market cap.
Financial Impact
Gross proceeds of ~$4 million, representing ~200% of current market cap; potential full dilution from warrants could add up to ~7.77 million additional shares.
Risk Factors
- Extreme dilution from the offering and potential exercise of warrants.
- Company may require additional funding, as stated in the safe harbor.
- Low market cap and high dilution risk could lead to further price erosion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311368 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | SC 13G | $0.2800 | awaiting T+60 | — | $0.1518 (−45.79%) |
Sep 15, 2026 5w ago | 8-K | $0.4310 | awaiting T+60 | — | $0.1518 (−64.78%) |
Jul 9, 2026 15w ago | EFFECT | $0.6755 $0.2882 | ▲ +57.34% | ▲ +58.97% | $0.1518 (+77.53%) |
Jul 2, 2026 16w ago | 8-K | $0.7330 $0.3080 | ▼ −57.98% | ▼ −61.55% | $0.1518 (−79.29%) |
Jun 26, 2026 17w ago | S-3 | $0.7190 $0.4480 | ▲ +37.69% | ▲ +42.08% | $0.1518 (+78.89%) |
Jun 15, 2026 19w ago | 8-K | $0.9183 $0.4797 | ▲ +47.76% | ▲ +48.77% | $0.1518 (+83.47%) |
Jun 12, 2026 19w ago | Press Release | $0.9183 $0.4797 | ▲ +47.76% | ▲ +48.77% | $0.1518 (+83.47%) |
Jun 12, 2026 19w ago | Press Release | $0.9180 $0.4530 | ▲ +50.65% | ▲ +51.31% | $0.1518 (+83.46%) |
May 14, 2026 23w ago | 8-K | $0.9560 $0.6699 | ▲ +29.93% | ▲ +34.44% | $0.1518 (+84.12%) |
Apr 30, 2026 25w ago | 10-K/A | $1.12 $0.6300 | ▼ −43.75% | ▼ −46.82% | $0.1518 (−86.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers